Last reviewed · How we verify

NCT00729768

A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation

Withdrawn Phase 2, PHASE3 Last updated 22 June 2017
What this trial tests

Phase 2, PHASE3 trial testing basiliximab in Kidney Transplantation. Withdrawn.

Quick facts

Lead sponsorGenentech, Inc.
PhasePhase 2, PHASE3
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment

Drugs / interventions tested

Conditions studied

Sponsor

Genentech, Inc. — full company profile →

Who can join

18 and older, any sex, with Kidney Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase II/III, randomized, open-label, active-controlled, multicenter trial to evaluate the safety and efficacy of efalizumab compared with cyclosporine (CsA), when both are given in combination with Mycophenolate Mofetil (MMF) and corticosteroids after induction therapy with basiliximab, as an immunosuppressant regimen in de novo renal transplantation. A total of 200 subjects undergoing either living or cadaveric renal transplantation will be randomly assigned 1:1 to receive either efalizumab + MMF + corticosteroids or CsA + MMF + corticosteroids.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Targeting co-stimulatory pathways: transplantation and autoimmunity.
    Ford ML, Adams AB, Pearson TC. · · 2014 · cited 130× · PMID 24100403 · DOI 10.1038/nrneph.2013.183

Verify or expand the search:

Other trials of basiliximab

Trials testing the same drug.

Other recruiting trials for Kidney Transplantation

Currently open trials in the same condition.

Other Genentech, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00729768.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing